Pharma/Device Combination Product Incentives Under Consideration At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
User fee reductions or waivers and exclusivity incentives are tools at FDA’s disposal to make cooperating with device firms more attractive to pharmaceutical manufacturers. Such incentives may still be insufficient to draw pharma manufacturers’ interest, an agency attorney says.